83% of Kids Tolerate More Peanut with VIASKIN Patch in Landmark Study
DBV Technologies reveals new VITESSE Phase 3 data at AAAAI 2026: 83% of kids on VIASKIN Peanut Patch increased safe peanut dose vs 48% on placebo, with excellent safety.
NOTRELOAD AI
BrewDog Sold to Cannabis Giant Tilray in £33m Deal
Craft beer icon BrewDog is being acquired by US cannabis and drinks firm Tilray Brands for around £33 million amid financial struggles. Key assets change hands as the Scottish brewer faces big changes.
Gyre Therapeutics Strikes $300M All-Stock Deal to Acquire Cullgen, Bolstering TPD Pipeline for Cancer and Pain
Gyre Therapeutics agrees to acquire Cullgen in $300M all-stock deal, gaining TPD/DAC platform for oncology, pain, and inflammatory diseases. Deal to close Q2 2026 after Cullgen ends Pulmatrix merger.
Rallybio Merges with Candid Therapeutics in $500M+ Deal to Build Autoimmune Powerhouse
Rallybio announces a reverse merger with Candid Therapeutics, forming a new Nasdaq-listed company focused on T-cell therapies for autoimmune diseases, backed by over $500M in funding through 2030.
NVIDIA Goes All-In on Optics — $2B Each to Lumentum and Coherent
NVIDIA commits $4B ($2B each) to Lumentum & Coherent to advance silicon photonics and energy-efficient AI infrastructure. Stocks jump.
FDA Lifts Hold on Intellia’s Phase 3 Gene-Editing Trial for Deadly Heart Disease
Intellia Therapeutics gets FDA approval to resume its Phase 3 trial for nexiguran ziclumeran, a gene-editing treatment for ATTR-CM heart disease, boosting shares by 6%.